Depo Provera Brain Tumor Information for New York Residents

Depo Provera Increases Risk of Brain Tumors in New York Women

Residents of New York are beginning to learn about risks associated with Depo Provera, commonly known as the birth control injection. Used for decades by women in New York, Depo Provera is the subject of a comprehensive new study out of France that links use of Depo Provera to a heightened risk of brain tumors known as meningiomas. Meningiomas are typically slow-growing tumors that form in the membranes surrounding the brain and spinal cord, which typically require brain surgery and/or radiation to treat, both of which carry their own host of life-threatening risks and dangers for New York women.

While the reasons behind the Depo Provera brain tumor link are as yet unclear, researchers found that using a high-progestin hormone treatment like Depo Provera or a generic alternative for at least a year results in a fivefold increase in meningioma. Attorneys handling Depo Provera brain tumor lawsuits for New York residents believe women and the family members of women who have been diagnosed with meningioma in New York after using Depo Provera for at least a year may be eligible for significant compensation. This page provides information for residents of New York on what medical researchers know about Depo Provera brain tumors.

Information on Depo Provera Birth Control Injection for New York Women

Depo Provera, or medroxyprogesterone acetate, is a contraceptive injection administered every three months to prevent pregnancy. It contains a synthetic form of the hormone progestin, which works by inhibiting ovulation, thickening cervical mucus to prevent sperm from reaching the egg, and thinning the uterine lining to prevent implantation. This method of birth control is popular among New York women seeking a long-acting, reversible contraceptive option that does not require daily administration.

Depo Provera was first developed by Upjohn Co. in 1959, and was initially approved by the FDA as a contraceptive in 1992. Today, Depo Provera is marketed in New York by Pfizer, the pharmaceutical giant that exceeded 58 billion revenues in 2023. There are also many generic versions of Depo Provera available in New York. More than one in five women have used Depo Provera or a generic in the United States, and the birth control injection is used by 74 million worldwide.

Two other drugs used in New York, medrogestone and promegestone, also deliver a high dose of progestin and are used to manage conditions such as endometriosis, polycystic ovary syndrome, and in hormone replacement therapy during menopause.

Depo Provera and Brain Tumors in New York

While Depo Provera is generally considered safe and effective for most women in New York, concerns have been raised regarding its potential side effects and long-term health risks. One area of concern to doctors and women in New York is the association between Depo Provera use and an increased risk of developing meningiomas, a type of brain tumor.

In addition to Depo Provera, medrogestone and promegestone both contain high doses of progestin and also increase the risk of brain tumors. Medrogestone and promegestone are used by women in New York to treat maladies including endometriosis, polycystic ovary syndrome, and in hormone replacement treatment during menopause.

In most cases, meningiomas in New York are not cancerous, yet it is misleading to use the word "benign" to describe these brain tumors. Women in New York who are diagnosed of meningioma face numerous significant dangers and risks. Located in the lining of the brain and spinal cord, treatment of meningioma brain tumors in New York often includes brain surgery and sometimes radiation. Risks of neurosurgery include seizures, brain damage, and other long-term repercussions. Even for New York patients whose initial treatment is successful, Depo Provera brain tumors can return again.

Depo Provera, medrogestone and promegestone have all been linked to an increased risk for a specific type of brain tumor called meningioma. Meningiomas are the most common type of primary brain tumor, accounting for approximately one-third of all brain tumors. They are more common in women than in men, leading researchers to investigate potential hormonal influences on their growth. In addition, progesterone hormone receptors have been found in more than 60% of meningiomas, leading researchers to suggest a possible link between the hormone and brain tumor development.

Women in New York were not aware of this risk because the drug inserts for medrogestone, promegestone, and Depo Provera do not contain brain tumor warnings. Symptoms of meningioma brain tumors include change in vision, hearing loss / ringing in the ears, loss of smell, headaches, memory loss, seizures, and weakened arms or legs.

Let Our Depo Provera Brain Tumor Lawyers Serving New York Help You

Our attorneys specialize in holding large corporations accountable when they've placed profits ahead of safety. Through settlements and winning verdicts, our attorneys have obtained millions for our clients. Let us help you today.

Depo Provera Brain Tumor Lawsuits for New York Residents

Filing a lawsuit will allow you to hold the pharmaceutical company accountable for damage it has caused you or a loved one, while also providing real compensation for your medical expenses, suffering and loss. Contact us today for a free consultation.